Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells

Cell Biology and Toxicology

Volumn 28, Issue 4, 2012, Pages 269-277

  Zhang, Yuntao ^a   Wang, Yong ^b   Yuan, Jianlin ^a   Qin, Weijun ^a   Liu, Fei ^a   Wang, Fuli ^a   Zhang, Geng ^a   Yang, Xiaojian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Chemoresistance; Docetaxel; Prostate cancer; TLR4

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOCETAXEL; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN PC 3; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAINING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAXOIDS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863724377     PISSN: 07422091     EISSN: 15736822     Source Type: Journal    
DOI: 10.1007/s10565-012-9221-2     Document Type: Article

References (45)

1. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001;26:61-6. (Pubitemid 32124712)
2. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Yokoyama M, Ohashi Y, Aso Y. Prostate Cancer Study Group. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006;98:573-9. (Pubitemid 44185879)
3. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007;25:4998-5008. (Pubitemid 350220434)
4. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011;71:2466-75.
5. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008;27:225-33.
6. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene. 2001;20:6073-83. (Pubitemid 32955050)
7. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu- Nosjean MC, Fridman WH, Damotte D, Sautès-Fridman C, Cremer I. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010;120:1285-97.
8. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol. 2010;28:4247-54.
9. Claerhout S, Verschooten L, Van Kelst S, De Vos R, Proby C, Agostinis P, Garmyn M. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. Int J Cancer. 2010;127:2790-803.
10. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-9. (Pubitemid 41103740)
11. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010;21:2135-44.
12. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res. 2009;29:2473-8.
13. Gomez LA, de Las Pozas A, Perez-stable C. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol Cancer Ther. 2006;5:1216-26. (Pubitemid 43881314)
14. González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, Escaff S, Vizoso FJ. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217-26.
15. Hammadi A, Billard C, Faussat AM, Kolb JP. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. Nitric Oxide. 2008;19:138-45.
16. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850-9. (Pubitemid 46412506)
17. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46:2876-84.
18. Huang HL, Chiang MF, Lin CW, Pu HF. Lipopolysaccharide directly stimulates aldosterone production via Toll-like receptor 2 and Toll-like receptor 4 related PI(3)K/Akt pathway in rat adrenal zona glomerulosa cells. J Cell Biochem. 2010;111:872-80.
19. Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, Kim CS. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol. 2010;184:2557-64.
20. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
21. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis in nonsmall cell lung cancer cells. Cancer Res. 2002;62:4929-37. (Pubitemid 34984416)
22. Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol. 2011;185:2376-81.
23. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001;142:4795-805. (Pubitemid 33022355)
24. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy- Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343-51.
25. Park JH, Yoon HE, Kim DJ, Kim SA, Ahn SG, Yoon JH. Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J Oral Pathol Med. 2011;40:187-93.
26. Pei Z, Lin D, Song X, Li H, Yao H. TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol. 2008;254:20-7.
27. Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer. 2011;104:613-9.
28. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, Nicolin A. Preferential chemosensitization of PTENmutated prostate cells by silencing the Akt kinase. Prostate. 2007;67:782-9. (Pubitemid 46711024)
29. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 1991;5:2652-60. (Pubitemid 21905816)
30. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57-63.
31. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res. 2011;71:1637-46.
32. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176:4894-901.
33. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29:3686-94.
34. Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A. Molecular chemotherapy and chemotherapy: a new front against late stage hormone refractory prostate cancer. Clin Cancer Res. 2011;17:4006-18.
35. Söderlund K, Pérez-Tenorio G, Stâl O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiationinduced apoptosis in breast cancer cells. Int J Oncol.2005;26:25-32.
36. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci. 2008;99:1901-7.
37. Sun Q, Zheng Y, Liu Q, Cao X. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. Int Immunopharmacol. 2008;8:1854-8.
38. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353-63.
39. Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12. (Pubitemid 39315317)
40. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:3854-61. (Pubitemid 40685606)
41. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-90.
42. Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest. 2009;39:157-64.
43. Wang GL, Jiang BH, Semenza GL. Effect of altered redox states on expression and DNA-binding activity of hypoxiainducible factor 1. Biochem Biophys Res Commun. 1995;212(2):550-6.
44. Xiao D, Singh SV. Phenethyl isothiocyanate sensitizes androgenindependent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. Pharm Res. 2010;27:722-31.
45. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 2006;97:1300-8. (Pubitemid 43907340)